Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Linking Cell Function and Gene Expression to Define Maturation of Stem-Cell Derived ß-Cells for the Treatment of Type 1 Diabetes
FY 2020-21
Summary
In July 2000, a type 1 diabetes treatment named the ""Edmonton protocol1"" was developed and has subsequently been used to treat thousands of patients worldwide, including ~400 in Canada. The Edmonton protocol uses insulin-producing islet cells from organ donors for transplantation into those with severe diabetes. Although significant progress has been made, new cell sources are needed to treat the millions living with the disease, since access to tissue from organ donors remains limited. Stem-cell derived β-cells (SCβ-cells) offer a promising alternative for cell replacement therapy since these can be grown in large amounts; however, key characteristics displayed by mature human β-cells, such as insulin secretion and cell excitability, remain blunted in SCβ-cells, reflecting immaturity after cellular differentiation. My project aims to understand the gene expression changes that underlie the mature functioning of primary human β-cells and the in vitro maturation of stem-cell derived β-cells to produce improved cell-based therapies for type 1 diabetes. I will use single-cell patch-clamp electrophysiology combined with RNA sequencing (Patch-Seq), in conjunction with a machine learning platform, to identify genes whose expression correlates with functional maturation of SCβ-cells. Identified targets will be validated, and the mechanism of function will be assessed using gene knockdown methods. Advances in this field will be critical for the development of cell replacement therapies for type 1 diabetes and will transform the lives of those in need of insulin producing cells to reduce the tremendous burden on Canada's health care system.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449353
Name
Maghera Jasmine
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Linking Cell Function and Gene Expression to Define Maturation of Stem-Cell Derived ß-Cells for the Treatment of Type 1 Diabetes
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Electrophysiology; Functional Maturation; Insulin Producing Cells; Insulin Secretion; Pancreatic Islets; Single Cell Analyses; Stem Cells; Transcriptomics; Transplantation; Type 1 Diabetes
Abstract
In July 2000, a type 1 diabetes treatment named the ""Edmonton protocol<sup>1</sup>"" was developed and has subsequently been used to treat thousands of patients worldwide, including ~400 in Canada. The Edmonton protocol uses insulin-producing islet cells from organ donors for transplantation into those with severe diabetes. Although significant progress has been made, new cell sources are needed to treat the millions living with the disease, since access to tissue from organ donors remains limited. Stem-cell derived β-cells (SCβ-cells) offer a promising alternative for cell replacement therapy since these can be grown in large amounts; however, key characteristics displayed by mature human β-cells, such as insulin secretion and cell excitability, remain blunted in SCβ-cells, reflecting immaturity after cellular differentiation. My project aims to understand the gene expression changes that underlie the mature functioning of primary human β-cells and the in vitro maturation of stem-cell derived β-cells to produce improved cell-based therapies for type 1 diabetes. I will use single-cell patch-clamp electrophysiology combined with RNA sequencing (Patch-Seq), in conjunction with a machine learning platform, to identify genes whose expression correlates with functional maturation of SCβ-cells. Identified targets will be validated, and the mechanism of function will be assessed using gene knockdown methods. Advances in this field will be critical for the development of cell replacement therapies for type 1 diabetes and will transform the lives of those in need of insulin producing cells to reduce the tremendous burden on Canada's health care system.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Maghera, Jasmine
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~